Amgen banks on speed to maintain edge in two hot cancer spaces

Amgen has a first-mover advantage in two of the hottest areas of cancer R&D -- K-Ras and bispecific antibodies. To stay ahead, it’s banking on a combination of rapid clinical development and moving to earlier disease settings.

EVP of R&D David Reese positions the company as an early player in immuno-oncology, largely on the basis of its strategy to choose spots carefully and build a niche...